Author(s): Azuma K, Ota K, Kawahara A, Hattori S, Iwama E, et al.
Background Recent clinical trials have shown that immune-checkpoint blockade yields a clinical response in a subset of individuals with advanced nonsmall-cell lung cancer (NSCLC). We examined whether the expression of programmed death–ligand 1 (PD-L1) is related to clinicopathologic or prognostic factors in patients with surgically resected NSCLC. Patients and methods The expression of PD-L1 was evaluated by immunohistochemical analysis in 164 specimens of surgically resected NSCLC. Cell surface expression of PD-L1 in NSCLC cell lines was quantified by flow cytometry. Results Expression of PD-L1 in tumor specimens was significantly higher for women than for men, for never smokers than for smokers, and for patients with adenocarcinoma than for those with squamous cell carcinoma. Multivariate analysis revealed that the presence of epidermal growth factor receptor gene (EGFR) mutations and adenocarcinoma histology were significantly associated with increased PD-L1 expression in a manner independent of other factors. Cell surface expression of PD-L1 was also significantly higher in NSCLC cell lines positive for activating EGFR mutations than in those with wild-type EGFR. The EGFR inhibitor erlotinib downregulated PD-L1 expression in the former cell lines but not in the latter, suggesting that PD-L1 expression is increased by EGFR signaling conferred by activating EGFR mutations. A high level of PD-L1 expression in resected tumor tissue was associated with a significantly shorter overall survival for NSCLC patients. Conclusions High expression of PD-L1 was associated with the presence of EGFR mutations in surgically resected NSCLC and was an independent negative prognostic factor for this disease.
Referred From: https://dx.doi.org/10.1093/annonc/mdu242
Author(s): Riaz SP, LÃ¼chtenborg M, Coupland VH, Spicer J, Peake MD, et al.
Author(s): Meza R, Meernik C, Jeon J, Cote ML
Author(s): Altan M, Chiang AC
Author(s): Shi Y, Xing P, Fan Y, Zhang X, Hu C, et al.
Author(s): Muenst S, Soysal SD, Tzankov A, Hoeller S
Author(s): Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X
Author(s): Qin T, Zeng YD, Qin G, Xu F, Lu JB, et al.
Author(s): Schmidt LH, KÃ¼mmel A, GÃ¶rlich D, Mohr M, BrÃ¶ckling S, et al.
Author(s): Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, et al.
Author(s): Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, et al.
Author(s): Micke P, Faldum A, Metz T, Beeh KM, Bittinger F, et al.
Author(s): Muenst S, Schaerli AR, Gao F, DÃ¤ster S, Trella E, et al.
Author(s): Schalper KA, Velcheti V, Carvajal D, Wimberly H, Brown J, et al.
Author(s): Ali HR, Glont SE, Blows FM, Provenzano E, Dawson SJ, et al.
Author(s): Wang A, Wang HY, Liu Y, Zhao MC, Zhang HJ, et al.
Author(s): Zhang Y, Wang L, Li Y, Pan Y, Wang R, et al.
Author(s): Ishii H, Azuma K, Kawahara A, Yamada K, Imamura Y, et al.
Author(s): Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, et al.
Author(s): Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, et al.